November 12, 2025 — Leads & Copy —
BOSTON and LONDON — Centessa Pharmaceuticals plc (Nasdaq: CNTA) has announced the pricing of its underwritten public offering of 11,627,907 American Depositary Shares (ADSs) at $21.50 per ADS, expecting gross proceeds of approximately $250 million before deductions.
All ADSs sold in the offering were offered by Centessa. The offering is expected to close around November 14, 2025, contingent upon standard closing conditions. The company has granted underwriters a 30-day option to buy up to 1,744,186 additional ADSs at the public offering price, minus underwriting discounts and commissions.
Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are joint book-running managers. Oppenheimer & Co., Truist Securities, and LifeSci Capital are co-lead managers.
The ADSs are offered under a registration statement on Form S-3, effective upon filing with the SEC on September 11, 2024. The final prospectus supplement and accompanying prospectus are available on the SEC’s website.
Copies of the final prospectus supplement may be obtained from:
- Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at Prospectus_Department@Jefferies.com;
- Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: (800) 808-7525 ext. 6105, email: syndicate@leerink.com;
- Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, telephone: (888) 474-0200, email: ecm.prospectus@evercore.com;
- Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: at (212) 518-9544, or by emailing GSEquityProspectusDelivery@guggenheimpartners.com.
Centessa Pharmaceuticals is a clinical-stage company aiming to transform patients’ lives through the discovery and development of new medicines. It is focused on pioneering new therapies, such as orexin receptor 2 (OX2R) agonists, for neurological, neurodegenerative, and neuropsychiatric disorders.
Kristen K. Sheppard, Esq., SVP of Investor Relations, can be contacted at investors@centessa.com.
Source: Centessa Pharmaceuticals plc
